Dr. Zankel co-founded and seed-funded Enabled Therapeutics in 2016. He is also the company’s chief science officer (CSO). Dr. Zankel began his career in drug-development as the fourth employee of BioMarin Pharmaceutical, in 1997, completing his tenure there as Senior Director of Research in 2005. He then co-founded Raptor Pharmaceuticals, in 2006, acting as CSO and head of discovery research until 2016, when Raptor was acquired. A direct descendant of the discovery group at Raptor, Enabled Therapeutics is focused on proprietary molecules conceived and developed to treat neuronal injury and degeneration. As an academic, Dr. Zankel was an NIH postdoctoral fellow at both the Plant Gene Expression Center in Berkeley, California and the Chemistry Department of the ETH, Zürich, Switzerland. The author of a number of scientific publications and patents, Todd earned a B.A. in Chemistry from Reed College in Portland, Oregon, and a Ph.D. in Chemistry from Columbia University, New York.
Menu